Drugs

, Volume 76, Issue 2, pp 263–273 | Cite as

Osimertinib: First Global Approval

AdisInsight Report
Part of the following topical collections:
  1. Topical Collection on Lung Cancer

Abstract

Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR. In November 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy. Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-positive NSCLC in several countries. Phase I trials in patients with advanced solid tumours are also being conducted. This article summarizes the milestones in the development of osimertinib leading to this first approval for NSCLC.

References

  1. 1.
    Liao BC, Lin CC, Yang JC. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015;27(2):94–101.PubMedCrossRefGoogle Scholar
  2. 2.
    Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev. 2014;40(8):917–26.PubMedCrossRefGoogle Scholar
  3. 3.
    Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015;16(9):e447–59.PubMedCrossRefGoogle Scholar
  4. 4.
    AstraZeneca Pharmaceuticals LP. Tagrisso™ (osimertinib) tablet, for oral use: US prescribing information. 2015. http://www.fda.gov. Accessed 10 Dec 2015.
  5. 5.
    US Food and Drug Administration. FDA approves new pill to treat certain patients with non-small cell lung cancer [media release]. http://www.fda.gov. Accessed 13 Nov 2015.
  6. 6.
    AstraZeneca. Tagrisso™ (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer [media release]. http://www.astrazeneca.com. Accessed 13 Nov 2015.
  7. 7.
    AstraZeneca. AstraZeneca annual report and form 20-F information 2014. 2014. http://www.astrazeneca.com. Accessed 10 Dec 2015.
  8. 8.
    Business Wire. AstraZeneca presents further evidence for the potential of AZD9291 in first-Line and pre-treated non-small cell lung cancer [media release]. http://www.businesswire.com. Accessed 8 Sep 2015.
  9. 9.
    European Medicines Agency. Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures. 2015. http://www.ema.europa.eu. Accessed 10 Dec 2015.
  10. 10.
    Lane EJ. AstraZeneca stands out again in China, hails AZD9291 in Japan [media release]. http://www.fiercepharmaasia.com. Accessed 5 Aug 2015.
  11. 11.
    AstraZeneca, MedImmune. AstraZeneca strengthens partnership with the University of Cambridge [media release]. http://www.astrazeneca.com. Accessed 16 Oct 2014.
  12. 12.
    AstraZeneca. AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations [media release]. http://www.astrazeneca.com. Accessed 22 Oct 2015.
  13. 13.
    Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–61.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–2.PubMedCrossRefGoogle Scholar
  15. 15.
    Planchard D, Loriot Y, Andre F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26(10):2073–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Kim TM, Song A, Kim DW, et al. Mechanisms of acquired resistance to AZD9291, a mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol. 2015. doi:10.1097/JTO.0000000000000688.PubMedCentralGoogle Scholar
  17. 17.
    Cross D, D’Cruz C, Eberlein C, et al. Targeting resistance in EGFR-mutant non-small cell lung cancer (NSCLC): preclinical evidence supporting the combination of EGFR tyrosine kinase inhibitors (TKIs) AZD9291 and gefitinib with molecularly targeted agents and immunotherapeutics [abstract no. 466P plus poster]. Ann Oncol. 2014;25(Suppl 4):iv155.Google Scholar
  18. 18.
    Thress KS, Yang JC-H, Ahn M-J, et al. Levels of EGFR T790M in plasma DNA as a predictive biomarker for response to AZD9291, a mutant-selective EGFR kinase inhibitor [abstract no. 1270P plus poster]. Ann Oncol. 2014;25(Suppl 4):iv446–7.Google Scholar
  19. 19.
    Thress K, Leeson J, Geradts J, et al. Design, execution, and preliminary biomarker results from paired tumor biopsy cohorts of the AZD9291 AURA trial [abstract no. MINI16.09]. J Thorac Oncol. 2015;10(9 Suppl 2):S320.Google Scholar
  20. 20.
    Goss GD, Yang JCH, Ahn M, et al. AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): pooled analysis from two phase II studies [abstract no. 3113 plus poster]. In: European Cancer Congress; 2015.Google Scholar
  21. 21.
    Planchard D, Dickinson PA, Brown KH, et al. Preliminary AZD9291 Western and Asian clinical pharmacokinetics (PK) in patients (pts) and healthy volunteers (HV): implications for formulation, dose and dosing frequency in pivotal clinical studies [abstract no. 464P plus poster]. Ann Oncol. 2014;25(Suppl 4):iv154–5.Google Scholar
  22. 22.
    Vishwanathan K, Dickinson PA, Bui K, et al. Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291 [abstract no. B153]. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2015.Google Scholar
  23. 23.
    Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99.PubMedCrossRefGoogle Scholar
  24. 24.
    Kim D, Yang J, Cross D, et al. Preclinical evidence and clinical cases of AZD9291 activity in EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases (BM) [abstract no. 456P plus poster]. Ann Oncol. 2014;25(Suppl 4):iv152.Google Scholar
  25. 25.
    Ahn MJ, Tsai CM, Yang JCH, et al. AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies [abstract no. 3083 plus poster]. In: European Cancer Congress; 2015.Google Scholar
  26. 26.
    Jänne PA, Ahn M-J, Kim D-W, et al. A phase I study of AZD9291 in patients with EGFR-TKI-resistant advanced NSCLC—updated progression free survival and duration of response data [abstract no. LBA3]. Ann Oncol. 2015;26(Suppl 1):i60.CrossRefGoogle Scholar
  27. 27.
    Yang JC, Ahn M, Ramalingam SS, et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study phase II extension cohort [abstract no. MINI16.06]. J Thorac Oncol. 2015;10(9 Suppl 2):S319.Google Scholar
  28. 28.
    Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study [abstract no. MINI16.08]. J Thorac Oncol. 2015;10(9 Suppl 2):S320.Google Scholar
  29. 29.
    Ryden A, Braam L, Martin M, et al. Patient experience of symptoms and side effects when treated with AZD9291 for advanced non-small-cell lung cancer: a qualitative interview sub-study [abstract no. 1551 plus poster]. In: European Cancer Congress; 2015.Google Scholar
  30. 30.
    Ryden A, Lawrance R, Papadakis K, et al. Patient-reported symptom response and impact of treatment with AZD9291 for advanced non-small-cell lung cancer [abstract no. 3030 plus poster]. In: European Cancer Congress; 2015.Google Scholar
  31. 31.
    Lee DH, Kim D-W, Ahn M-J, et al. AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: a phase I study [abstract no. PR07]. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2015.Google Scholar
  32. 32.
    Hochmair M, Holzer S, Setinek U, et al. EGFR resistant T790M mutation in NSCLC: real-life data of patients treated with AZD9291 [abstract no. P49]. Wien Klin Wochenschr. 2015;127(19–20):831.Google Scholar
  33. 33.
    Ramalingam SS, Yang JCH, Lee CK, et al. AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): results from a phase 1 expansion cohort [abstract no. 8000]. J Clin Oncol. 2015;33(15 Suppl).Google Scholar
  34. 34.
    Ramalingam SS, Yang J-H, Lee C, et al. AZD9291 in treatment-naive EGFRm advanced NSCLC: AURA first-line cohort [abstract no. MINI16.07]. J Thorac Oncol. 2015;10(9):S319–20.Google Scholar
  35. 35.
    Oxnard GR, Ramalingam SS, Ahn MJ, et al. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer [abstract no. 2509]. J Clin Oncol. 2015;33(15 Suppl).Google Scholar
  36. 36.
    Bloomberg Business. AstraZeneca temporarily halts cancer drug combination trials [media release]. http://www.bloomberg.com. Accessed 9 Oct 2015.
  37. 37.
    AstraZeneca. AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291 [media release]. http://www.astrazeneca.com. Accessed 28 Jul 2014.
  38. 38.
    Roche. Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy [media release]. http://www.roche.com. Accessed 30 Jul 2015.
  39. 39.
    Wu Y-L, Papadimitrakopoulou VA, Ghiorghiu S, et al. AURA3 design: a randomised, phase III study of AZD9291 versus second-line chemotherapy for patients (pts) with EGFR-TKI-resistant (T790M) advanced non-small cell lung cancer [abstract no. 140TiP]. Ann Oncol. 2015;26(Suppl 1):i43.CrossRefGoogle Scholar
  40. 40.
    Ramalingam SS, Rukazenkov Y, Thomas K, et al. A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naive patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation [abstract no. TPS8102]. J Clin Oncol. 2015;33(15 Suppl).Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations